FDA approves first generic twice-yearly HIV prevention shot
The FDA approved a generic lenacapavir. It is expected to cost about $40 a year in 120 low- and middle-income countries.
Why it matters
Cheap prevention could cut HIV infections in poorer countries.
Background
Lenacapavir is injected twice a year.
The story so far
- FDA approves first generic twice-yearly HIV prevention shot
- FDA approves generic twice-yearly HIV prevention shot
- FDA approves low-cost HIV prevention shot
Sources
- CBC News ↗Nov 2, 4:58 PM ET
- AFP via France 24 via Wikipedia ↗November 2, 2026
This summary was written automatically from the reporting linked above; follow the sources for the full story. How One Turn works.